Researchers centered at Nagoya University develop a nanowire device able to detect microscopic levels of urinary markers potentially implicated in cancer.
Cells communicate with each other through a number of different mechanisms.
Some of these mechanisms are well-known:
in animals, for example, predatory threats can drive the release of norepinephrine, a hormone that travels through the bloodstream and triggers heart and muscle cells to initiate a “fight-or-flight” response.
A far less familiar mode of cellular transport is the extracellular vesicle (EV).
EVs can be thought of as small “chunks” of a cell that are able to pinch off and circulate throughout the body to deliver messenger cargo to other cells.
These messengers have become increasingly recognized as crucial mediators of cell-to-cell communication.
In a new study reported in Science Advances, researchers centered at Nagoya University have developed a novel medical device that can efficiently capture these EVs, and potentially use them to screen for cancer.
“EVs are potentially useful as clinical markers.
The composition of the molecules contained in an EV may provide a diagnostic signature for certain diseases,” lead author Takao Yasui explains.
“The ongoing challenge for physicians in any field is to find a non-invasive diagnostic tool that allows them to monitor their patients on a regular basis — for example, a simple urine test.”
Among the many molecules EVs have been found to harbor are microRNAs, which are short pieces of ribonucleic acid that play diverse roles in normal cellular biology.
Critically, the presence of certain microRNAs in urine might serve as a red flag for serious conditions such as bladder and prostate cancer.
While this important cargo could therefore theoretically aid physicians in cancer diagnoses, there are still many technological hurdles that need to be overcome.
One such hurdle: finding a feasible method to capture EVs in sufficient quantities to analyze them in a routine clinical setting.
“The content of EVs in urine is extremely low, at less than 0.01% of the total fluid volume. This is a major barrier to their diagnostic utility,” Yasui notes.
“Our solution was to embed zinc oxide nanowires into a specialized polymer to create a material that we believed would be highly efficient at capturing these vesicles.
Our findings suggest that the device is indeed quite efficient.
We obtained a collection rate of over 99%, surpassing ultracentrifugation as well as other methods that are currently being used in the field.”
To test the practicality of their device, the research team compared the microRNAs of EVs isolated from healthy patients with those isolated from patients who were already diagnosed with bladder, prostate, and other forms of cancer.
Notably, their technique required only 1 milliliter of urine — far more than the typical “deposit” provided during a routine checkup — and found a substantially greater number and different types of microRNAs compared with the standard ultracentrifugation approach.
“Finding a specific, reproducible marker to help confirm a cancer diagnosis is difficult.
This is especially true for microRNAs, which are a relatively new class of markers in the field,” co-author Yoshinobu Baba explains.
“Sometimes finding just one reliable microRNA is considered a success.
Using this approach, we were surprised to find that not just one, but whole combinations of microRNAs might be associated with different types of cancers.
The findings are preliminary, of course, but we hope our device can help to lay the groundwork for easier ways to diagnose life-threatening diseases as early as possible.”
- Takao Yasui, Takeshi Yanagida, Satoru Ito, Yuki Konakade, Daiki Takeshita, Tsuyoshi Naganawa, Kazuki Nagashima, Taisuke Shimada, Noritada Kaji, Yuta Nakamura, Ivan Adiyasa Thiodorus, Yong He, Sakon Rahong, Masaki Kanai, Hiroshi Yukawa, Takahiro Ochiya, Tomoji Kawai, Yoshinobu Baba. Unveiling massive numbers of cancer-related urinary-microRNA candidates via nanowires. Science Advances, 2017; 3 (12): e1701133 DOI: 10.1126/sciadv.1701133